Healthcare Roundup – Vir Biotech IDs coronavirus-binding antibodies, FDA clears Baxter metabolic monitoring device

医疗保健精选——Vir Biotech识别冠状病毒结合抗体,FDA批准百特的代谢监测装置
Published on: February 12, 2020
Author: Amy Liu

Vir Biotech IDs coronavirus-binding antibodies; shares up 4% premarket

  • Vir Biotechnology (NASDAQ:VIR) perks up 4% premarket on light volume in reaction to its announcement that it has identified two monoclonal antibodies that bind the coronavirus causing the current outbreak, COVID-19 (formerly 2019-nCov).
  • The company says it is assessing neutralization with a pseudo-virus and is working with international partners to assess neutralization with the live virus.

FDA clears Baxter metabolic monitoring device

  • Baxter International (NYSE:BAX) and licensor COSMED announce FDA clearance of Q-NRG+, a portable metabolic monitoring device based on indirect calorimetry technology. It is used to measure resting energy expenditure in spontaneously breathing and ventilated patients in a healthcare facility setting.
  • Market launch will commence at the ASPEN 2020 Nutrition Science & Practice Conference in Tampa, FL, March 28-31.

Transfer of Otezla OK’d in Canada

  • Health Canada has signed off on the Marketing Authorization transfer of Otezla (apremilast) from Celgene to Amgen (NASDAQ:AMGN) for plaque psoriasis and psoriatic arthritis.
  • Amgen acquired global rights in November 2019.

Merck’s Keytruda meets PFS endpoint in TNBC study

  • Merck (NYSE:MRK) announces that a Phase 3 clinical trial, KEYNOTE-355, evaluating the combination of Keytruda (pembrolizumab) and chemo in patients with metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 (Combined Positive Score at least 10) met one of the dual primary endpoints, progression-free survival (PFS).
  • In a first-line setting, treatment with the Keytruda combo resulted in a statistically significant increase in PFS compared to chemo alone.
  • The trial will continue unchanged in order to assess the other primary endpoint of overall survival (OS).
  • Detailed data will be submitted for presentation at a future medical conference and reviewed with regulatory authorities.
  • Shares up 1% premarket on light volume.

Elanco to divest European rights to certain Bayer assets

  • Aimed at securing the regulatory nod in Europe for its previously announced acquisition of Bayer’s (OTCPK:BAYRY) animal health business, Elanco Animal Health (NYSE:ELAN) has agreed to divest EU and UK rights to Bayer’s Drontal and Profender product lines to Vetoquinol SA.
  • Elanco says its talks with regulators about the transaction are “progressing as planned.”
  • ELAN is up 1% after hours.

Biotechnology Coronavirus COVID-19 Genomics Healthcare Services Life Science Medical Device Novel Coronavirus Pneumonia Pharmaceutical